Selective D1 agonism but not D2 antagonism is reflected in cAMP and cGMP levels in rat CSF

Brain Research Bulletin

Volumn 81, Issue 6, 2010, Pages 549-551

  Torremans, An ^a   Van Hemelrijck, An ^a   Straetemans, Roel ^a   Vanhoof, Greet ^a   Van Den Kieboom, Gerd ^a   Drinkenburg, Wilhelmus H ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Cerebrospinal fluid (CSF); Cyclic AMP; Cyclic GMP; Dopamine; Rat

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; CYCLIC AMP; CYCLIC GMP; HALOPERIDOL;

ANIMAL EXPERIMENT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; MALE; NEUROCHEMISTRY; NONHUMAN; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; BENZAZEPINES; CEREBROSPINAL FLUID; CYCLIC AMP; CYCLIC GMP; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 76749084276     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.12.004     Document Type: Article

References (26)

1. Altar C., Boyar W., and Kim H. Discriminatory roles for D1 and D2 dopamine receptor subtypes in the in vivo control of neostriatal cyclic GMP. Eur. J. Pharmacol. 181 1-2 (1990) 17-21
2. Belmaker R., Zohar J., and Ebstein R. Cyclic nucleotides in mental disorder. Adv. Cyclic Nucleotide Res. 12 (1980) 187-198
3. Biederman J., Rimon R., Ebstein R., Zohar J., and Belmaker R. Neuroleptics reduce spinal fluid cyclic AMP in schizophrenic patients. Neuropsychobiology 2 (1976) 324-327
4. Biggio G., Costa E., and Guidotti A. Pharmacologically induced changes in the 3′5′cyclic guanisine monophosphate content of rat cerebellar cortex: difference between apomorphine, haloperidol and harmaline. J. Pharmacol. Exp. Ther. 200 (1977) 207-215
5. Breese G., Mueller R., and Mailman R. Effect of dopaminergic agonists and antagonists on in vivo cyclic nucleotide content: relation of guanisine 3′5′monophosphate (cGMP) changes in cerebellum to behavior. J. Pharmacol. Exp. Ther. 209 (1979) 262-270
6. Domek-Lopacinska K., and Strosznajder J.B. Cyclic GMP metabolism and its role in brain physiology. J. Physiol. Pharmacol. 56 (2005) 15-34
7. Gattaz W., Cramer H., and Beckmann H. Low CSF concentrations of cyclic GMP in schizophrenia. Br. J. Psychiatry 142 (1983) 288-291
8. Gattaz W., Cramer H., and Beckmann H. Haloperidol increases the cerebrospinal fluid concentrations of cyclic GMP in Schizophrenic patients. Biol. Psychiatry 19 8 (1984) 1229-1235
9. Greengard P. The neurobiology of slow synaptic transmission. Science 294 5544 (2001) 1024-1030
10. Guevara-Guzmán R., Emson R., and Kendrick K. Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP. J. Neurochem. 62 (1994) 807-810
11. Horstmann R., Hammers R., Clarenbach P., and Cramer H. The effects of probenecid on cyclic adenosine 3′,5′-monophosphate levels in cerebrospinal fluid and on brain phosphodiesterase activity in the rat. Arch. Psychiatr. Nervenkr. 233 (1983) 71-76
12. Hutson P., and Suman-Chauhan N. Activation of postsynaptic striatal dopamine receptors: monitored by efflux of cAMP in vivo. Neuropharmacology 29 11 (1990) 1011-1016
13. Ilzecka J. Decreased cerebrospinal fluid cGMP levels in patients with amyotrophic lateral sclerosis. J. Neural Transm. 111 (2004) 167-172
14. Marte A., Pepicelli O., Cavallero A., Raiteri M., and Fedele E. In vivo effects of phosphodiesterase inhibition on basal cyclic guanosine monophosphate levels in the prefrontal cortex, hippocampus and cerebellum of freely moving rats. J. Neurosci. Res. 86 (2008) 3338-3347
15. Martinez M., Fernandes E., Frank A., Guaza C., de la Fuente M., and Hernanz A. Increased cerebrospinal fluid cAMP levels in Alzheimer's disease. Brain Res. 849 (1999) 265-267
16. Missale C., Nash R., Robinson S., Jaber M., and Caron M. Dopamine receptors: from structure to function. Physiol. Rev. 78 1 (1998) 189-225
17. Muly C. Signal transduction abnormalities in schizophrenia: the cAMP system. Psychopharmacol. Bull. 36 4 (2002) 92-105
18. Navarro J., Jiménez-Jiménez F., Molina J., Benito-León J., Cisneros E., Gasalla T., Orti-Pareja M., Tallon-Barranco A., de Bustos F., and Arenas J. Cerebrospinal fluid cyclic guanosine 3′5′monophosphate levels in Parkinson's disease. J. Neurol. Sci. 155 (1998) 92-94
19. Nishi A., Kuroiwa M., Miller D., O'Callaghan J., Bateup H., Shuto T., Sotogaku N., Fukuda T., Heintz N., Greengard P., and Snyder G. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J. Neurosci. 28 (2008) 10460-10471
20. Piedrafita B., Cauli O., Montoliu C., and Vicente F. The function of the glutamate-nitric oxide-cGMP pathway in brain in vivo and learning ability decrease in parallel in mature compared with young rats. Learn. Mem. 14 (2007) 254-258
21. Schmidt C., Chapin D., Cianfrogna J., Corman M., Hajos M., Harms J., Hoffman W., Lebel L., McCarthy S., Nelson F., Proulx-LaFrance C., Majchrzak M., Ramirez A., Schmidt K., Seymour P., Siuciak J., Tingley F., Williams R., Verhoest P., and Menniti F. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther. 325 2 (2008) 681-690
22. Tsang D., Lal S., Sourkes T., Ford R., and Aronoff A. Studies on cyclic AMP in different compartments of cerebrospinal fluid. J. Neurol. Neurosurg. Psychiatry 39 (1976) 1186-1190
23. Tsou K., Snyder G., and Greengard P. Nitric oxide/cGMP pathway stimulates phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, in the substantia nigra. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 3462-3465
24. Volicer L., Beal M., Direnfeld M., Marquis J., and Albert M. CSF cyclic nucleotides and somatostatin in Parkinson's disease. Neurology 36 (1986) 89-92
25. West A., and Grace A. The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity states and electrophysiological properties of striatal medium spiny neurons recorded in vivo. J. Neurosci. 24 (2004) 1924-1935
26. Wood P. Pharmacology of the second messenger, cyclic guanosine 3′5′monophosphate, in the cerebellum. Pharmacol. Rev. 43 (1991) 1-25